title: Evaluation of the efficacy of triple therapy regimen for Helicobacter pylori eradication in gastrectomized patients with gastric adenocarcinoma.
abstract: BACKGROUND
  The cause of cancer in the gastric stump is multifactorial, and Helicobacter pylori is one of these factors. Its eradication has been recommended; however, there are few studies about of H. pylori eradication in gastrectomized patients.
  
  
  METHODS
  Twenty gastrectomized patients with gastric adenocarcinoma and Roux-en-Y reconstruction (study group) infected by H. pylori were compared with nongastrectomized patients (control group) also infected by H. pylori. The presence of H. pylori was determined by the ultra-quick urease test and from a histological sample obtained by endoscopy. Both groups received the same triple therapy regimen.
  
  
  RESULTS
  The rate of eradication of H. pylori in the study group was 90% and in the control group, it was 85%. Sex, age, and postoperative time did not influence the rate of eradication.
  
  
  CONCLUSIONS
  There were no differences in the efficacy of H. pylori eradication between the two groups; therefore, the triple therapy regimen is effective for the eradication of H. pylori in gastrectomized patients with a Roux-en-Y reconstruction.
authors.affiliation: Department of Surgery, Fellow of Universidade Federal de São Paulo -- Escola-Paulista de Medicina, São Paulo, Brazil.
authors.forename: Jose Luiz
authors.initials: JL
authors.lastname: Bertoli Neto
authors.forename: Laercio Gomes
authors.initials: LG
authors.lastname: Lourenço
authors.forename: Cícero Fernando
authors.initials: CF
authors.lastname: Bertoli
authors.forename: Fábio Samsonowski
authors.initials: FS
authors.lastname: Ulbrich
authors.forename: Antoninho Ricardo
authors.initials: AR
authors.lastname: Sabbi
authors.forename: Alexandre Galvão
authors.initials: AG
authors.lastname: Bueno
mesh_terms: D053799:2-Pyridinylmethylsulfinylbenzimidazoles / Q000627:therapeutic use; D000230:Adenocarcinoma / Q000188:drug therapy* / Q000382:microbiology / Q000601:surgery; D000328:Adult; D000368:Aged; D000658:Amoxicillin / Q000627:therapeutic use; D000900:Anti-Bacterial Agents / Q000627:therapeutic use*; D000897:Anti-Ulcer Agents / Q000627:therapeutic use*; D016022:Case-Control Studies; D017291:Clarithromycin / Q000627:therapeutic use; D004359:Drug Therapy, Combination; D005260:Female; D005743:Gastrectomy; D016481:Helicobacter Infections / Q000188:drug therapy* / Q000382:microbiology / Q000601:surgery; D016480:Helicobacter pylori; D006801:Humans; D064747:Lansoprazole; D008297:Male; D008875:Middle Aged; D013274:Stomach Neoplasms / Q000188:drug therapy* / Q000382:microbiology / Q000601:surgery
chemical_list: D053799:2-Pyridinylmethylsulfinylbenzimidazoles; D000900:Anti-Bacterial Agents; D000897:Anti-Ulcer Agents; D064747:Lansoprazole; D000658:Amoxicillin; D017291:Clarithromycin